

Patricia T Greipp

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5046547/publications.pdf>

Version: 2024-02-01

168
papers

3,042
citations

159358

30
h-index

197535

49
g-index

169
all docs

169
docs citations

169
times ranked

4637
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL. <i>Blood</i> , 2017, 129, 3419-3427.	0.6	335
2	DNAJB1-PRKACA is specific for fibrolamellar carcinoma. <i>Modern Pathology</i> , 2015, 28, 822-829.	2.9	142
3	Idiopathic Systemic Capillary Leak Syndrome (Clarkson's Disease): The Mayo Clinic Experience. <i>Mayo Clinic Proceedings</i> , 2010, 85, 905-912.	1.4	137
4	Diagnosis and Management of Waldenström Macroglobulinemia. <i>JAMA Oncology</i> , 2017, 3, 1257.	3.4	110
5	Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. <i>Blood</i> , 2016, 128, 1234-1245.	0.6	105
6	Anti-CD20 monoclonal antibody therapy in multiple myeloma. <i>British Journal of Haematology</i> , 2008, 141, 135-148.	1.2	98
7	Gastroblastoma harbors a recurrent somatic MALAT1-GLI1 fusion gene. <i>Modern Pathology</i> , 2017, 30, 1443-1452.	2.9	93
8	Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract. <i>Blood</i> , 2018, 131, 2262-2266.	0.6	77
9	Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. <i>Cancer Letters</i> , 2016, 380, 163-173.	3.2	72
10	Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. <i>Journal of Hematology and Oncology</i> , 2019, 12, 73.	6.9	71
11	Molecular cytogenetic analysis for TFE3 rearrangement in Xp11.2 renal cell carcinoma and alveolar soft part sarcoma: validation and clinical experience with 75 cases. <i>Modern Pathology</i> , 2014, 27, 113-127.	2.9	65
12	Cytogenetic abnormalities in multiple myeloma: association with disease characteristics and treatment response. <i>Blood Cancer Journal</i> , 2020, 10, 82.	2.8	59
13	Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. <i>Blood Advances</i> , 2020, 4, 3509-3519.	2.5	58
14	Fibrolamellar carcinoma in the Carney complex: PRKAR1A loss instead of the classic DNAJB1-PRKACA fusion. <i>Hepatology</i> , 2018, 68, 1441-1447.	3.6	48
15	Molecular testing for the clinical diagnosis of fibrolamellar carcinoma. <i>Modern Pathology</i> , 2018, 31, 141-149.	2.9	47
16	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88L265P Mutations. <i>American Journal of Clinical Pathology</i> , 2016, 145, 843-851.	0.4	43
17	False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms. <i>Haematologica</i> , 2019, 104, e248-e251.	1.7	43
18	Immunohistochemistry for TFE3 lacks specificity and sensitivity in the diagnosis of TFE3-rearranged neoplasms: a comparative, 2-laboratory study. <i>Human Pathology</i> , 2019, 87, 65-74.	1.1	41

#	ARTICLE	IF	CITATIONS
19	Impact of acquired del(17p) in multiple myeloma. <i>Blood Advances</i> , 2019, 3, 1930-1938.	2.5	41
20	Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. <i>British Journal of Haematology</i> , 2020, 188, 394-403.	1.2	41
21	Histopathologic and Cytogenetic Features of Pulmonary Adenoid Cystic Carcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1570-1575.	0.5	40
22	IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. <i>Leukemia</i> , 2020, 34, 1373-1382.	3.3	40
23	Natural history of multiple myeloma with de novo del(17p). <i>Blood Cancer Journal</i> , 2019, 9, 32.	2.8	38
24	Polypoid fibroadipose tumors of the esophagus: "giant fibrovascular polyp" or liposarcoma? A clinicopathological and molecular cytogenetic study of 13 cases. <i>Modern Pathology</i> , 2018, 31, 337-342.	2.9	37
25	Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. <i>Blood Cancer Journal</i> , 2019, 9, 73.	2.8	37
26	Loss of TNFAIP3 enhances MYD88L265P-driven signaling in non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2018, 8, 97.	2.8	36
27	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013, 163, 326-333.	1.2	35
28	Mate pair sequencing improves detection of genomic abnormalities in acute myeloid leukemia. <i>European Journal of Haematology</i> , 2019, 102, 87-96.	1.1	35
29	Loss of BAP1 Expression in Atypical Mesothelial Proliferations Helps to Predict Malignant Mesothelioma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 256-263.	2.1	34
30	Analysis of MDM2 Amplification in 43 Endometrial Stromal Tumors. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 576-583.	0.9	33
31	Impact of MYD88 ^{L265P} mutation status on histological transformation of Waldenström Macroglobulinemia. <i>American Journal of Hematology</i> , 2020, 95, 274-281.	2.0	33
32	Implications of MYC Rearrangements in Newly Diagnosed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020, 26, 6581-6588.	3.2	32
33	Prevalence, breakpoint distribution, and clinical correlates of t(5;12). <i>Cancer Genetics and Cytogenetics</i> , 2004, 153, 170-172.	1.0	31
34	A simple additive staging system for newly diagnosed multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, 21.	2.8	30
35	Loss of p16 INK4A Expression and Homozygous CDKN2A Deletion Are Associated with Worse Outcome and Younger Age in Thymic Carcinomas. <i>Journal of Thoracic Oncology</i> , 2017, 12, 860-871.	0.5	28
36	Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance. <i>Leukemia</i> , 2018, 32, 1811-1815.	3.3	28

#	ARTICLE	IF	CITATIONS
37	Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 103.	2.8	27
38	De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. <i>Modern Pathology</i> , 2018, 31, 705-717.	2.9	25
39	Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms. <i>Cancer Genetics</i> , 2018, 228-229, 197-217.	0.2	25
40	Clinical utility of myb rearrangement detection and p63/p40 immunophenotyping in the diagnosis of adenoid cystic carcinoma of minor salivary glands: a pilot study. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 121, 282-289.	0.2	21
41	KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory. <i>Genes Chromosomes and Cancer</i> , 2018, 57, 541-546.	1.5	21
42	Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma. <i>Blood Advances</i> , 2020, 4, 2236-2244.	2.5	20
43	BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia. <i>Cancer Genetics</i> , 2016, 209, 223-228.	0.2	19
44	Acute leukemias harboring <i>KMT2A/MLLT10</i> fusion: a 10-year experience from a single genomics laboratory. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 567-577.	1.5	19
45	Assessment of isochromosome 12p and 12p abnormalities in germ cell tumors using fluorescence in situ hybridization, single-nucleotide polymorphism arrays, and next-generation sequencing/mate-pair sequencing. <i>Human Pathology</i> , 2021, 112, 20-34.	1.1	19
46	Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorders with Biallelic Rearrangements of <i>DUSP22</i> . <i>Journal of Investigative Dermatology</i> , 2013, 133, 1680-1682.	0.3	17
47	Atypical lipomatous tumour/well-differentiated liposarcoma and dedifferentiated liposarcoma in patients aged 40 years: a study of 116 patients. <i>Histopathology</i> , 2019, 75, 833-842.	1.6	16
48	Characterization of a cryptic <i>IGH/CCND1</i> rearrangement in a case of mantle cell lymphoma with negative <i>CCND1</i> FISH studies. <i>Blood Advances</i> , 2019, 3, 1298-1302.	2.5	16
49	Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining. <i>Cancer Research</i> , 2021, 81, 3333-3346.	0.4	16
50	FISH Scoring for CLL: Comparison of Methods That Assess Round Versus Non-Round Nuclei. <i>Blood</i> , 2011, 118, 3538-3538.	0.6	16
51	Characterization of <i>TCF3</i> rearrangements in pediatric B-lymphoblastic leukemia/lymphoma by mate-pair sequencing (MPseq) identifies complex genomic rearrangements and a novel <i>TCF3/TEF</i> gene fusion. <i>Blood Cancer Journal</i> , 2019, 9, 81.	2.8	14
52	Elucidating a false-negative <i>MYC</i> break-apart fluorescence in situ hybridization probe study by next-generation sequencing in a patient with high-grade B-cell lymphoma with <i>IGH/MYC</i> and <i>IGH/BCL2</i> rearrangements. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a004077.	0.5	14
53	The Prognostic Role of <i>MYC</i> Structural Variants Identified by NGS and FISH in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 5430-5439.	3.2	14
54	The Utilization of Chromosomal Microarray Technologies for Hematologic Neoplasms. <i>American Journal of Clinical Pathology</i> , 2018, 150, 375-384.	0.4	13

#	ARTICLE	IF	CITATIONS
55	Tetraploidy is associated with poor prognosis at diagnosis in multiple myeloma. American Journal of Hematology, 2019, 94, E117-E120.	2.0	13
56	Systematic use of fluorescence <i>in situ</i> hybridisation and clinicopathological features in the screening of PDGFRB rearrangements of patients with myeloid/lymphoid neoplasms. Histopathology, 2020, 76, 1042-1054.	1.6	13
57	<i>FGFR1</i> and <i>FGFR2</i> in fibrolamellar carcinoma. Histopathology, 2016, 68, 686-692.	1.6	12
58	A Test Utilization Approach to the Diagnostic Workup of Isolated Eosinophilia in Otherwise Morphologically Unremarkable Bone Marrow. American Journal of Clinical Pathology, 2018, 150, 421-431.	0.4	12
59	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia. American Journal of Hematology, 2021, 96, 945-953.	2.0	12
60	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia. British Journal of Haematology, 2021, 195, 210-216.	1.2	12
61	Rapid assessment of hyperdiploidy in plasma cell disorders using a novel multiparametric flow cytometry method. American Journal of Hematology, 2019, 94, 424-430.	2.0	11
62	Increased ERBB2 Gene Copy Numbers Reveal a Subset of Salivary Duct Carcinomas with High Densities of Tumor Infiltrating Lymphocytes and PD-L1 Expression. Head and Neck Pathology, 2020, 14, 951-965.	1.3	11
63	Impact of Novel Targeted Therapies and Cytogenetic Risk Groups on Outcome After Allogeneic Transplantation for Adult ALL. Transplantation and Cellular Therapy, 2021, 27, 165.e1-165.e11.	0.6	11
64	Treatment outcome of clonal cytopenias of undetermined significance: a single-institution retrospective study. Blood Cancer Journal, 2021, 11, 43.	2.8	11
65	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations. Blood Cancer Journal, 2019, 9, 20.	2.8	10
66	Novel t(1;8)(p31.3;q21.3) <i>NFIA</i> - <i>RUNX1T1</i> Translocation in an Infant Erythroblastic Sarcoma. American Journal of Clinical Pathology, 2021, 156, 129-138.	0.4	10
67	PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. International Journal of Gynecological Pathology, 2018, 37, 537-546.	0.9	9
68	Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients. Leukemia and Lymphoma, 2019, 60, 990-999.	0.6	9
69	Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group. Modern Pathology, 2021, , .	2.9	9
70	Myeloid malignancies in cancer patients treated with poly(ADP-ribose) polymerase (PARP) inhibitors: a case series. Blood Cancer Journal, 2022, 12, 11.	2.8	9
71	Brain Metastasis of Crystal-Deficient, CD68-Positive Alveolar Soft Part Sarcoma: Ultrastructural Features and Differential Diagnosis. Ultrastructural Pathology, 2015, 39, 69-77.	0.4	8
72	Detection of a cryptic NUP214/ABL1 gene fusion by mate-pair sequencing (MPseq) in a newly diagnosed case of pediatric T-lymphoblastic leukemia. Journal of Physical Education and Sports Management, 2019, 5, a003533.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Constitutional chromosome rearrangements that mimic the 2017 world health organization acute myeloid leukemia with recurrent genetic abnormalities: A study of three cases and review of the literature. <i>Cancer Genetics</i> , 2019, 230, 37-46.	0.2	8
74	Fluorescence in situ hybridisation for TP63 rearrangements in T cell lymphomas: single-site experience of 470 patients and implications for clinical testing. <i>Histopathology</i> , 2020, 76, 481-485.	1.6	8
75	Detection of cryptic CCND1 rearrangements in mantle cell lymphoma by next generation sequencing. <i>Annals of Diagnostic Pathology</i> , 2020, 46, 151533.	0.6	8
76	Myeloid malignancies with 5q and 7q deletions are associated with extreme genomic complexity, biallelic TP53 variants, and very poor prognosis. <i>Blood Cancer Journal</i> , 2021, 11, 18.	2.8	8
77	Clinical utility of next generation sequencing to detect IGH/IL3 rearrangements [t(5;14)(q31.1;q32.1)] in B-lymphoblastic leukemia/lymphoma. <i>Annals of Diagnostic Pathology</i> , 2021, 53, 151761.	0.6	8
78	Ovarian Hemangiomas Do Not Harbor EWSR1 Rearrangements. <i>International Journal of Gynecological Pathology</i> , 2015, 34, 437-444.	0.9	7
79	Environmental exposures as a risk factor for fibrolamellar carcinoma. <i>Modern Pathology</i> , 2017, 30, 892-896.	2.9	7
80	Cytogenetic Evolution in Myeloid Neoplasms at Relapse after Allogeneic Hematopoietic Cell Transplantation: Association with Previous Chemotherapy and Effect on Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 782-789.	2.0	7
81	Identification of a Novel ZBTB20-JAK2 Fusion by Mate-Pair Sequencing in a Young Adult With B-Lymphoblastic Leukemia/Lymphoma. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1381-1384.	1.4	7
82	Aurora kinase B-phosphorylated HP1± functions in chromosomal instability. <i>Cell Cycle</i> , 2019, 18, 1407-1421.	1.3	7
83	Large Chromosomal Rearrangements Yield Biomarkers to Distinguish Low-Risk From Intermediate- and High-Risk Prostate Cancer. <i>Mayo Clinic Proceedings</i> , 2019, 94, 27-36.	1.4	7
84	Use of mate-pair sequencing to characterize a complex cryptic BCR/ABL1 rearrangement observed in a newly diagnosed case of chronic myeloid leukemia. <i>Human Pathology</i> , 2019, 89, 109-114.	1.1	7
85	Characterization of a cryptic PML-RARA fusion by mate-pair sequencing in a case of acute promyelocytic leukemia with a normal karyotype and negative RARA FISH studies. <i>Leukemia and Lymphoma</i> , 2020, 61, 975-978.	0.6	7
86	Cryptic and atypical KMT2A-USP2 and KMT2A-USP8 rearrangements identified by mate pair sequencing in infant and childhood leukemia. <i>Genes Chromosomes and Cancer</i> , 2020, 59, 422-427.	1.5	7
87	Clinical and biological characteristics and prognostic impact of somatic GATA2 mutations in myeloid malignancies: a single institution experience. <i>Blood Cancer Journal</i> , 2021, 11, 122.	2.8	7
88	Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms. <i>American Journal of Hematology</i> , 2022, 97, 1013-1022.	2.0	7
89	Typical, atypical and cryptic t(15;17)(q24;q21) (PML::RARA) observed in acute promyelocytic leukemia: A retrospective review of 831 patients with concurrent chromosome and PML::RARA dual-color dual-fusion FISH studies. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 629-634.	1.5	7
90	Characterizing false-positive fluorescence in situ hybridization results by mate-pair sequencing in a patient with chronic myeloid leukemia and progression to myeloid blast crisis. <i>Cancer Genetics</i> , 2020, 243, 48-51.	0.2	6

#	ARTICLE	IF	CITATIONS
91	Comparative study of therapy-related and de novo adult B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2022, 196, 963-968.	1.2	6
92	Prognostic significance of acquired 1q22 gain in multiple myeloma. <i>American Journal of Hematology</i> , 2021, . .	2.0	6
93	MYC break-apart FISH probe set reveals frequent unbalanced patterns of uncertain significance when evaluating aggressive B-cell lymphoma. <i>Blood Cancer Journal</i> , 2021, 11, 184.	2.8	6
94	CD117, BAP1, MTAP, and TdT Is a Useful Immunohistochemical Panel to Distinguish Thymoma from Thymic Carcinoma. <i>Cancers</i> , 2022, 14, 2299.	1.7	6
95	Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	6
96	Secondary Philadelphia chromosome and erythrophagocytosis in a relapsed acute myeloid leukemia after hematopoietic cell transplantation. <i>Cancer Genetics</i> , 2014, 207, 268-271.	0.2	5
97	Defining Lymphoplasmacytic Lymphoma. <i>American Journal of Clinical Pathology</i> , 2018, 150, 168-176.	0.4	5
98	Hepatic YAP1-TFE3 Rearranged Epithelioid Hemangioendothelioma. <i>Case Reports in Gastrointestinal Medicine</i> , 2019, 2019, 1-5.	0.2	5
99	Characterization of a rarely reported STAT5B/RARA gene fusion in a young adult with newly diagnosed acute promyelocytic leukemia with resistance to ATRA therapy. <i>Cancer Genetics</i> , 2019, 237, 51-54.	0.2	5
100	Identification of a novel KMT2A/GIMAP8 gene fusion in a pediatric patient with acute undifferentiated leukemia. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 108-111.	1.5	5
101	BRAF Rearrangements and BRAF V600E Mutations Are Seen in a Subset of Pancreatic Carcinomas With Acinar Differentiation. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 840-845.	1.2	5
102	Clinical utility of fluorescence in situ hybridization-based diagnosis of BCR-ABL1 like (<sc>P</sc>hiladelphia chromosome like) <sc>B</sc>-acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E68-E72.	2.0	4
103	Identification of adult Philadelphia-like acute lymphoblastic leukemia using a FISH-based algorithm distinguishes prognostic groups and outcomes. <i>Blood Cancer Journal</i> , 2021, 11, 156.	2.8	4
104	Gene fusions in gastrointestinal tract cancers. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 285-297.	1.5	4
105	A near-haploid clone harboring a BCR/ABL1 gene fusion in an adult patient with newly diagnosed B-cell acute lymphoblastic leukemia. <i>Genes Chromosomes and Cancer</i> , 2019, 58, 665-668.	1.5	3
106	Secondary acquisition of BCR-ABL1 fusion in de novo GATA2-MECOM positive acute myeloid leukemia with subsequent emergence of a rare KMT2A-ASXL2 fusion. <i>Cancer Genetics</i> , 2020, 241, 67-71.	0.2	3
107	Spurious CD34 expression in B-cell lymphoma due to nonspecific binding to <sc>PerCP-Cy5.5</sc> fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall. <i>Cytometry Part B - Clinical Cytometry</i> , 2022, 102, 326-328.	0.7	3
108	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. <i>American Journal of Hematology</i> , 2018, 93, E355-E357.	2.0	2

#	ARTICLE	IF	CITATIONS
109	Whole Genome Mate-pair Sequencing of Plasma Cell Neoplasm as a Novel Diagnostic Strategy: A Case of Unrecognized t(2;11) Structural Variation. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 598-602.	0.2	2
110	Multiple isodicentric Y chromosomes in myeloid malignancies: a unique cytogenetic entity and potential therapeutic target. <i>Leukemia and Lymphoma</i> , 2019, 60, 821-824.	0.6	2
111	Case Report with Review of the Literature: Uveal Melanoma in a Patient with Carney Complex – Another Rare Component of the Syndrome?. <i>Ocular Oncology and Pathology</i> , 2020, 6, 311-317.	0.5	2
112	Adult Philadelphia-like B-cell acute lymphoblastic leukemia: Characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, 7022-7022.	0.8	2
113	Increased complexity of t(11;14) rearrangements in plasma cell neoplasms compared with mantle cell lymphoma. <i>Genes Chromosomes and Cancer</i> , 2021, 60, 678-686.	1.5	2
114	Plasma Cell Folate Receptor Overexpression Differentiates Multiple Myeloma from Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma.. <i>Blood</i> , 2004, 104, 3649-3649.	0.6	2
115	Mediastinal B-cell lymphoma with MYC, BCL2, and BCL6 rearrangements. <i>Journal of Hematopathology</i> , 2022, 15, 151-155.	0.2	2
116	Impact of clone size with a single cytogenetic abnormality on the revised International Prognostic Scoring System in myelodysplastic syndromes. <i>American Journal of Hematology</i> , 2018, 93, E398-E401.	2.0	1
117	Characterization of a cryptic KMT2A/AFF1 gene fusion by mate-pair sequencing (MPseq) in a young adult with newly diagnosed B-lymphoblastic leukemia. <i>Journal of Hematopathology</i> , 2019, 12, 99-104.	0.2	1
118	Siblings with ETV6/RUNX1-positive B-lymphoblastic leukemia: A single site experience and review of the literature. <i>Annals of Diagnostic Pathology</i> , 2020, 48, 151588.	0.6	1
119	Twin-to-twin transmission of transient abnormal myelopoiesis without constitutional trisomy 21: A case report. <i>Cancer Genetics</i> , 2020, 244, 62-64.	0.2	1
120	Rare MDM2 amplification in a fat-predominant angiomyolipoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 661-666.	1.4	1
121	Characteristics of patients with myelodysplastic syndrome with balanced translocations. <i>British Journal of Haematology</i> , 2020, 190, 244-248.	1.2	1
122	Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system. <i>Annals of Hematology</i> , 2020, 99, 513-518.	0.8	1
123	IgM Associated Light Chain (AL) Amyloidosis: Delineating Disease Biology with Clinical, Genomic and Bone Marrow Morphological Features. <i>Blood</i> , 2018, 132, 4460-4460.	0.6	1
124	In-111DAC Is a Novel Technique To Image Multiple Myeloma.. <i>Blood</i> , 2006, 108, 3488-3488.	0.6	1
125	OUP accepted manuscript. <i>Laboratory Medicine</i> , 2021, , .	0.8	1
126	Whole Arm Duplication of 1q in Myeloid Neoplasm, with Emphasis On Derivative (1;7)(q10;p10).. <i>Blood</i> , 2009, 114, 4238-4238.	0.6	1

#	ARTICLE	IF	CITATIONS
127	Impact of MYD88L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia. <i>Blood</i> , 2018, 132, 2884-2884.	0.6	1
128	A Novel Approach to Risk Stratification in Multiple Myeloma Using ISS Stage and FISH. <i>Blood</i> , 2019, 134, 1800-1800.	0.6	1
129	Detection of a Cryptic <i>KMT2A/AFDN</i> Gene Fusion [ins(6;11)(q27;q23q23)] in a Pediatric Patient with Newly Diagnosed Acute Myeloid Leukemia. <i>Laboratory Medicine</i> , 2022, 53, e95-e99.	0.8	1
130	Characterization of Atypical t(11;14) CCND1/IGH Translocations in Multiple Myeloma. <i>Blood</i> , 2021, 138, 3771-3771.	0.6	1
131	Clinical Characteristics and Prognosis of Thirty-Three Patients with Myeloid Neoplasms and DDX41 Mutation: Mayo Clinic Experience. <i>Blood</i> , 2021, 138, 3691-3691.	0.6	1
132	Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias. <i>Blood</i> , 2020, 136, 26-27.	0.6	1
133	A Novel <i>USP25::PDGFRA</i> Gene Fusion in a 78 Year Old Patient with a Myeloid Neoplasm. <i>Laboratory Medicine</i> , 2022, 53, e134-e138.	0.8	1
134	Identification of EWSR1 rearrangements in patients with immature hematopoietic neoplasms: A case series and review of literature. <i>Annals of Diagnostic Pathology</i> , 2022, 58, 151942.	0.6	1
135	Apparent coexistence of <i>ETV6::RUNX1</i> and <i>KMT2A::MLLT3</i> fusions due to a nonproductive <i>KMT2A</i> rearrangement in B-ALL. <i>Leukemia and Lymphoma</i> , 2022, , 1-4.	0.6	1
136	A 10-Year Review of KMT2A Gene Fusion Partners Observed in Pediatric T-Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience. <i>American Journal of Clinical Pathology</i> , 2018, 150, S132-S132.	0.4	0
137	Use of Mate-Pair Sequencing (MPseq) to Elucidate a Complex BCR-ABL1 Rearrangement Observed in a Newly Diagnosed Case of Chronic Myeloid Leukemia. <i>American Journal of Clinical Pathology</i> , 2018, 150, S131-S132.	0.4	0
138	14. Clinical mate-pair sequencing reveals complex genomic rearrangements in B-lymphoblastic leukemia/lymphoma (B-ALL). <i>Cancer Genetics</i> , 2018, 224-225, 55-56.	0.2	0
139	12. Mate pair sequencing: Unveiling underappreciated complexity and providing clarity to the previously unanswered questions of cytogenetics. <i>Cancer Genetics</i> , 2018, 224-225, 54-55.	0.2	0
140	13. Clinical utility of mate pair sequencing to detect diagnostic and prognostic chromosomal rearrangements and copy number changes in patients with acute myeloid leukemia. <i>Cancer Genetics</i> , 2018, 224-225, 55.	0.2	0
141	Characterization of a t(1;2)(p36;p21) involving the PRDM16 gene region by mate-pair sequencing (MPseq) in a patient with newly diagnosed acute myeloid leukemia with myelodysplasia-related changes. <i>Journal of Hematopathology</i> , 2019, 12, 85-90.	0.2	0
142	Mate pair sequencing outperforms fluorescence in situ hybridization and improves diagnostic yield in the genomic characterization of multiple myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e58.	0.2	0
143	Detection of a Cryptic <i>EP300/ZNF384</i> Gene Fusion by Chromosomal Microarray and Next-Generation Sequencing Studies in a Pediatric Patient with B-Lymphoblastic Leukemia. <i>Laboratory Medicine</i> , 2021, 52, 297-302.	0.8	0
144	Erythroblastic sarcoma transformation from a chronic myeloid neoplasm with FGFR1 rearrangement presenting as a pleural effusion: a case report. <i>Journal of Hematopathology</i> , 2021, 14, 157-162.	0.2	0

#	ARTICLE	IF	CITATIONS
145	Dual Primary IGH Translocations in Multiple Myeloma: A Novel Finding. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e710-e713.	0.2	0
146	Myeloma with t(11;14) and CD20+ Plasma Cells: Response to Rituximab.. <i>Blood</i> , 2005, 106, 5178-5178.	0.6	0
147	Isolated Trisomy 8 in the Myelodysplastic Syndromes.. <i>Blood</i> , 2009, 114, 2785-2785.	0.6	0
148	FISH Redoux " A Novel Way to Emulate CLL Leukemic Cells From Buffy Coat Samples. <i>Blood</i> , 2010, 116, 3606-3606.	0.6	0
149	Very High Risk CLL Characterized by a "Double Hit" Clone with Both 11q22 and 17p13 Deletion.. <i>Blood</i> , 2012, 120, 2486-2486.	0.6	0
150	Outcome of Patients Younger Than 50 Years Old Diagnosed with Myelodysplastic Syndromes (MDS): Single Institution Experience. <i>Blood</i> , 2016, 128, 5541-5541.	0.6	0
151	Utilization of Mate-Pair Sequencing to Characterize Complex and Novel TCF3 Translocations. <i>Blood</i> , 2016, 128, 4086-4086.	0.6	0
152	Outcome of patients younger than 50 years old diagnosed with myelodysplastic syndromes (MDS): Single institution experience.. <i>Journal of Clinical Oncology</i> , 2017, 35, e18560-e18560.	0.8	0
153	The impact of clonal size on the revised international prognostic scoring system (R-IPSS) in myelodysplastic syndromes (MDS) with a single cytogenetic abnormality.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7068-7068.	0.8	0
154	The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome per 2017 WHO guideline compared to de novo MDS.. <i>Journal of Clinical Oncology</i> , 2018, 36, e19026-e19026.	0.8	0
155	Abstract 655: Hyperdiploidy in plasma cell disorders using multi-parametric flow cytometry (MFC) vs. FISH. , 2018, , .		0
156	Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System. <i>Blood</i> , 2018, 132, 5510-5510.	0.6	0
157	Impact of Acquired Del(17p) in Patients with Multiple Myeloma. <i>Blood</i> , 2018, 132, 4449-4449.	0.6	0
158	Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.. <i>Journal of Clinical Oncology</i> , 2019, 37, 3144-3144.	0.8	0
159	Identification of Targetable Tumor Associated Proteins in Adult T-Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) Including a Novel CC-Chemokine 4 (CCR4)-Positive T-ALL/LBL with Unique Immunophenotype. <i>Blood</i> , 2019, 134, 5210-5210.	0.6	0
160	Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort. <i>Blood</i> , 2019, 134, 2588-2588.	0.6	0
161	Utilizing next-generation sequencing to characterize a case of acute myeloid leukemia with t(4;12)(q12;p13) in the absence of ETV6/CHIC2 and ETV6/PDGFR A gene fusions. <i>Cancer Genetics</i> , 2021, 260-261, 1-5.	0.2	0
162	Unique Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (trALL) Following Therapy for Multiple Myeloma (MM). <i>Blood</i> , 2021, 138, 2285-2285.	0.6	0

#	ARTICLE	IF	CITATIONS
163	False-Negative Centromere 15 Probe Results in Association with African Ancestry in Plasma Cell Dyscrasias. <i>Blood</i> , 2021, 138, 4101-4101.	0.6	0
164	The Prognostic Significance of Acquired 1q22 Gain in Multiple Myeloma. <i>Blood</i> , 2020, 136, 9-10.	0.6	0
165	Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study. <i>Blood</i> , 2020, 136, 44-44.	0.6	0
166	Heterogeneity of <i>MYC</i> Abnormalities in Multiple Myeloma. <i>Blood</i> , 2020, 136, 2-3.	0.6	0
167	Clinical Value of Next Generation Sequencing in the Detection of Recurring Structural Rearrangements and Copy Number Abnormalities in Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 21-22.	0.6	0
168	BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers. <i>Ocular Oncology and Pathology</i> , 2022, 8, 22-29.	0.5	0